NUVB Sep 2024 0.500 call
| Previous Close | 2.6500 |
| Open | N/A |
| Bid | 2.3000 |
| Ask | 3.3000 |
| Strike | 0.50 |
| Expire Date | 2024-09-20 |
| Day's Range | 2.6500 - 2.6500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 1 |
Business WireNuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting
NEW YORK, June 01, 2024--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, announced that results from the pivotal Phase 2 TRUST-I study conducted in China evaluating taletrectinib, its investigational next-generation ROS1 tyrosine kinase inhibitor (TKI), were published today in the Journal of Clinical Oncology (JCO) and will be highlighted in an oral presentation at the 2024 American Society of Clinical
Business WireNuvation Bio to Present at the Jefferies Global Healthcare Conference
NEW YORK, May 29, 2024--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, announced today that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will participate in a hybrid presentation at the Jefferies Global Healthcare Conference in New York, NY on Wednesday, June 5, 2024, at 1:30 p.m. ET.
Business WireNuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update
NEW YORK, May 14, 2024--Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the first quarter ended March 31, 2024, and provided a business update.
